Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns
This is a paid press release. Contact the press release distributor directly with any inquiries.
A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns
PR Newswire
Tue, February 17, 2026 at 11:27 PM GMT+9 2 min read
In this article:
SCIB.ST
-3.60%
STOCKHOLM, Feb. 17, 2026 /PRNewswire/ – SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, announces that results from a new study will be presented in an oral presentation at the AAAAI conference in Philadelphia February 27 - March 2.
The study from Icahn school of Medicine of Mount Sinai in New York was conducted on newborns who have a first-degree relative affected by atopic disease - meaning they had an increased risk of developing atopic dermatitis.
The study included 19 infants, among whom Nevisense successfully identified those who later developed atopic dermatitis (AD). Within the first year of life, eight of the nineteen infants developed AD, and their Nevisense scores at birth were significantly higher.
Conclusion from the study was ‘Higher EIS scores, suggestive of impaired skin barrier, within the first week of life were significantly associated with development of AD in the first year of life.’
“These are very promising results, demonstrating the potential of Nevisense to predict atopic dermatitis. The findings are especially interesting, as we are simultaneously conducting larger studies on predicting atopic dermatitis in children,” said Pia Renaudin, CEO of SciBase.
The abstract for the oral presentation at AAAAI can be found here: Assessing the Skin Barrier Using Electrical Impedance Spectroscopy in Newborns to Predict Development of Atopic Dermatitis - Journal of Allergy and Clinical Immunology.
**For further information please contact:
**Pia Renaudin, CEO,
Phone. +46732069802
E-mail: pia.renaudin@scibase.com
**
Certified Advisor (CA):
**DNB Carnegie Investment Bank AB (publ)
Tel: +46 8 588 68 570
E-mail: certifiedadviser@carnegie.se
About SciBase and Nevisense
_SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management. _
_Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. _
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
_The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: __
This information was brought to you by Cision
The following files are available for download:
Cision
View original content:
Terms and Privacy Policy
Privacy Dashboard
More Info